ProCE Banner Activity

CAPELLA: Wk 52 Results With Long-Acting SC Lenacapavir in Randomized and Nonrandomized Cohorts of Persons With Multidrug-Resistant HIV

Slideset Download
Conference Coverage

At Week 52, maintenance therapy with SC lenacapavir in combination with an optimized background regimen was associated with virologic suppression in 78% of heavily treatment–experienced persons with multidrug-resistant HIV infection.

Released: November 03, 2022


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare